Beral V, Evans S, Shaw H, Milton G
Br J Cancer. 1984 Nov;50(5):681-5. doi: 10.1038/bjc.1984.236.
In a case control study of 287 women aged 15-24 years with malignant melanoma and 574 matched controls, findings relating to oral contraceptive use and other hormone use are reported. Ever having used oral contraceptives was not associated with an increased risk of melanoma (relative risk for ever use of the pill = 1.0). Women with melanoma were, however, more likely to have taken oral contraceptives for long periods of time in the past, the relative risk associated with oral contraceptive use for a total duration of 5 years or longer which had begun at least 10 years before the melanoma was diagnosed being 1.5 (95% confidence interval 1.03 to 2.14) This elevated risk persisted after controlling for the reported hair and skin colour, frequency of moles on the body, place of birth, and measures of sunlight and fluorescent light exposure. Cases were more likely than controls to have used hormones to regulate their periods, hormonal replacement therapy and be given hormone injections to suppress lactation, the respective relative risks being 1.9, 1.4 and 1.4, but none differed significantly from 1.0. These findings suggest that prolonged oral contraceptive use may, after a lag of 10 years or so, increase the risk of malignant melanoma.
在一项针对287名年龄在15至24岁之间的恶性黑色素瘤女性患者及574名匹配对照者的病例对照研究中,报告了与口服避孕药使用及其他激素使用相关的研究结果。曾经使用过口服避孕药与黑色素瘤风险增加无关(使用避孕药的相对风险 = 1.0)。然而,黑色素瘤女性患者过去更有可能长期服用口服避孕药,在黑色素瘤确诊前至少10年开始使用口服避孕药且总时长达到或超过5年的相对风险为1.5(95%置信区间1.03至2.14)。在控制了报告的头发和皮肤颜色、身体上痣的数量、出生地以及阳光和荧光暴露量等因素后,这种升高的风险依然存在。病例组比对照组更有可能使用激素来调节经期、进行激素替代疗法以及接受抑制泌乳的激素注射,各自的相对风险分别为1.9、1.4和1.4,但均与1.0无显著差异。这些研究结果表明,长期使用口服避孕药可能在大约10年的滞后时间后增加恶性黑色素瘤的风险。